ggwpq, I don't disagree with you. Litigation is the backbone of the generic businesses model. This situation is unusual. The SNDA would give them access to a market they already have access to. Is there a benefit for them to do it. Is there any risk for them in court? Sleven,
ggwpq, One other thing. The validity of the R-IT patents may be determined by Amarin v Health Net. If the court finds the patents to be valid in one suit, I don't know if the validity can be challenged in a separate suit. Sleven,
ggw, Seems like DR Reddy is now the Leader of the Pack in generic Vascepa (gV).
What we have to keep in mind is that todays Generic Company's - are Giants compared to Amarin who 'as you pointed out' have build their entire existents around fights in Courts WW.
Case against Amarin is 'Boring Everyday' for the experts Lawyers in Patents an Law surrounding Bio employed in Generic Companies.
Just have a Look at the history of DR Reddy. The fights around Amarin and gV is 'everyday' for a company like that.
We all know Marjac and SCOTUS is a 'Very LONG Shot' - but for the American user of drugs' - exposing the fraudulent methods used by Generic companies in US Courts - this could be a 'wake up call' in realizing what is really happening in this field.
News 
Market Data 
Discover 
